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Autoimmune cytopenias are a recognized complication of hematopoietic stem cell transplant (HSCT), and
are considered to be a feature of chronic graft-versus-host disease (cGVHD). We report on a cohort of
very young infants (#3 months of age) receiving HSCT from unrelated donor umbilical cord blood for ge-
netic disorders who developed posttransplant autoimmune cytopenias at an increased rate compared to
older aged controls. These infants received a conditioning regimen consisting of busulfan, cyclophosphamide,
and antithymocyte globulin (ATG). All infants received HLA mismatched unrelated umbilical cord blood as
graft source. GVHD prophylaxis was either cyclosporine 1 methylprednisolone (n 5 16) or cyclosporine
1mycophenolate mofetil (n5 3). Engraftment, acute GVHD (aGVHD) and cGVHD, survival, treatment-re-
lated mortality (TRM), and deaths were evaluated. Ten patients developed cGVHD manifesting as autoim-
mune cytopenias at a median 247 days posttransplant with a cumulative incidence of 44% (95%
confidence interval [CI] 21%-68%) and 56% (95% CI 32%-80%) at 1 and 2 years, respectively. In 6 of 10 pa-
tients developing autoimmune cytopenias, cGVHD presented as autoimmune cytopenia de novo. The cyto-
penias observed included anemia (n5 4), thrombocytopenia (n5 1), anemiawith thrombocytopenia (n5 3),
and pancytopenia (n5 2). No graft factors were identified as being significant to development of cGVHD. All
patients responded to treatment with methylprednisolone, azithioprine 6 rituximab. One patient required
splenectomy. We hypothesize that posttransplant immunosuppression interferes with normal immune on-
togeny creating immune dysregulation and graft directed cell destruction. Alternative strategies to prevent
GVHD should be considered for this unique patient population.
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Autoimmune cytopenias are a recognized compli-
cation after allogeneic hematopoietic stem cell
transplantation (HSCT), and are considered to be
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(cGVHD) when another symptom of cGVHD is
present [1,2]. In adults, the incidence of autoimmune
hemolytic anemia (AIHA) is 3%-4% in patients receiv-
ing either conventional or T cell-depleted grafts [3-5].
A slightly higher rate of 6% has been the reported in
the pediatric literature [6,7]. There are limited reports
about autoimmune cytopenias and cGVHD in very
young babies undergoing HSCT. Over the past de-
cade, we have transplanted a cohort of very young
babies with early infantile lysosomal storage diseases
and other genetic disorders.Wehave observed a higher
than expected rate of autoimmune cytopenias in these
infants and describe the cases in this report. We pro-
pose that autoimmune cytopenias can be a primary
manifestation of cGVHD in young pediatric patients
undergoing allogeneic HSCT.
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Patients
Between September 1998 and April 2007, 19 con-
secutive infants (#3 months of age) diagnosed with
early infantile lysosomal storage diseases (n 5 18) or
hemoglobinopathies (n 5 1) who were referred to
our center for transplantation and who lacked appro-
priate HLA matched related donors received cord
blood transplants from unrelated donors. Fourteen
were diagnosed prenatally and 5 were diagnosed at
birth. All diagnoses were confirmed prior to trans-
plant. Eight patients were enrolled in an institu-
tional-based phase I/II study of cord blood
transplantation for the treatment of nonmalignant dis-
eases. Ten patients were enrolled on the Cord Blood
Transplantation Study (COBLT) [8], and 1 patient
was enrolled in a phase I trial using ex vivo expansion
of ALDH cells [9]. All studies were approved by the in-
stitutional review board of Duke University Medical
Center. Written informed consent was obtained
from the infant’s parents before enrollment.
Selection of Donors
Intermediate-resolution typing for HLA class I (A
and B) and high resolution for HLA-DRB1 were used
for donor selection. The cord blood unit with the
highest number of nucleated cells (minimum, 3 
107/kg of recipient body weight) and closest HLA
match (minimum 4 of 6 HLA loci match) was selected.
Units were tested to ensure that the donor was neither
affected with nor a carrier of the condition for which
the infant was being transplanted.
Transplantation Procedure
Cryopreserved units of cord blood were thawed
and washed per the procedure of Rubinstein et al.
[10]. For the single patient on the ALDH trial, the
80% fraction was transplanted using conventional
methods, whereas the 20% fraction was sorted to iso-
late ALDH bright cells that were subsequently primed
ex vivo for 5 days using cytokines before infusion [9].
All thawed cord blood units were tested for total num-
ber of nucleated cells (TNC), clonal hematopoietic
progenitor cells, CD341 and CD31 cells, cell viability,
ABO and Rh typing, and microbial cultures (bacteria
and fungal).
Conditioning Regimen
The conditioning regimen for all patients included
16 doses of busulfan (Bu; 20 mg/m2 orally) from days
29 through 26; 4 doses of cyclophosphamide (Cy;
50 mg/m2 i.v.) from days 25 through 22; and 3 doses
of equine antithymocyte globulin (ATG; 30 mg/kg
i.v.) from days 23 through 21. Bu pharmacokinetics
were monitored with the first dose to target steady-state concentrations between 600-900 ng/mL. Patients
received phenytoin during Bu as seizure prophylaxis
and mesna during Cy for prophylaxis against hemor-
rhagic cystitis.
Posttransplant Regimen and Supportive Care
All children received prophylaxis against GVHD
with cyclosporine (CSA) 1 methylprednisone (n 5
16) or CSA 1 mycophenolate mofetil (MMF; n 5 3).
CSA was dosed to target levels between 200 and 300
ng/mL, and MMF was dosed at 15 mg/kg/dose i.v.
every 8 hours. GVHD prophylaxis was continued at
full dose for 6-9 months, then weaned as tolerated.
Treatment options for GVHD were based on severity
and included topical steroids, dose escalation of meth-
ylprednisone, change to tacrolimus, or addition of
daclizumab (Hoffmann-LaRoche, Nutley, NJ).
All patients were nursed in reverse isolation rooms
under positive pressure and HEPA filtration. Standard
prophylaxis was used against pneumocystis carinii,
acyclovir for viral, and voriconazole for fungal infec-
tions. Empiric antibiotic treatment was started with
the first febrile episode and continued through en-
graftment. Intravenous immune globulin (500 mg/
kg/dose) was administered weekly through day 100
then monthly through 1 year, then weaned as toler-
ated. As prophylaxis against veno-occlusive disease
(VOD), a continuous infusion of low-dose heparin
was used through day 28. Patients received transfu-
sions of leukocyte-depleted, irradiated-packed red
blood cells and platelets. Granulocyte-colony stimu-
lating factor (G-CSF) was administered from day 0 un-
til hematopoietic recovery and then was weaned.
Confirmation of engraftment was performed using
fluorescein in situ hybridization (FISH) or restricted
fragment length polymorphism (RFLP).
Study Subjects
Potential study subjects were identified by retro-
spective review of the transplant program research da-
tabase using age at transplant as initial criteria. To be
eligible for the study, patients had to be #3 months
of age at transplant, recipients of unrelated UCBT
with myeloablative conditioning, and have a diagnosis
of a nonmalignant disorder. Data was collected via
chart review for demographics, information regarding
cord blood unit, complications following transplant
including diagnosis, treatment, and response to treat-
ment of an autoimmune cytopenia. Data were com-
pared to 141 older aged historic and contemporary
controls at our center.
Laboratory Evaluation
Autoimmune hemolytic anemia was defined as de-
velopment of anemia in a patient with stable engraft-
ment where there was a hemoglobin drop of .2 g/dL,
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patients, and evidence of hemolysis by positive direct
antiglobulin test (DAT) and/or indirect Coomb’s
test, peripheral blood cell morphology, reticulocyte
count, and bilirubin level. The DAT was performed
to detect the presence of IgG or IgM antibodies and
complement on the patient’s red blood cells (Immu-
cor, Norcross, GA). If initial testing was positive, fur-
ther testing was conducted to determine if the
reaction was the result of IgG and/or complement
specifically C3. If IgG antibodies were present, an el-
uate was prepared and tested to determine antibody
specificity. Thrombocytopenia was defined as platelet
count \50,000 cells/mL. Neutropenia was present
if the absolute neutrophil count was \500/mm3.
Direct and indirect antiplatelet antibody testing was
performed if thrombocytopenia was present. Neutro-
phil cytoplasmic antibodies were enumerated when
possible.
Acute and Chronic GVHD (aGVHD, cGHVD)
Scoring
The severity of aGVHDwas scored using standard
criteria [11]. cGVHDwas scored using National Insti-
tute of Health (NIH) consensus criteria [1]. However,
patients with isolated immune cytopenias were also
scored as having cGVHD.
Statistical Analysis
Neutrophil engraftment was defined as the first
day of 3 consecutive days of an absolute neutrophil
count (ANC) of $500 donor cells/mm3; plateletengraftment was defined as the day of achieving an un-
transfused count of$50,000 platelets/mm3 for 7 days.
aGVHD was scored as the maximum grade in all pa-
tients within 100 days [11] and the cGVHD at the
highest level per consensus criteria [1]. The probabil-
ities of neutrophil and platelet engraftment, aGVHD,
and cGVHD and cytopenia were estimated using the
cumulative-incidence-function method [12]. Neutro-
phil engraftment, platelet engraftment, aGVHD, and
cGVHD and cytopenia were assessed in patients sur-
viving past day 15 and treating death as a competing
risk. Differences between subgroups were compared
using Grays K-Sample Test [13]. The probability of
overall survival (OS) was calculated with the use of
the Kaplan-Meier estimator [14] and differences be-
tween groups were compared using the log-rank statis-
tics [15]. Analyses were completed using the SAS
system, version 8.2, and R, version 2.1.1.
RESULTS
Patients Characteristics
From September 1998 through April 2007, 19 very
young infants (11 males, 8 females) received cord
blood transplants from unrelated donors. The median
weight and age at transplantation were 4.20 kg (range:
2.74 to 6.75) and 36 days (range: 18 to 117 days),
respectively (Table 1). Diagnoses includedKrabbe dis-
ease (n 5 12), Hurler’s syndrome (MPS I; n 5 2),
Hunter’s syndrome (MPS II; n 5 2), Metachromatic
Leukodystrophy (n 5 1), Tay Sachs disease (n 5 1)
and Beta-Thalassemia Major (n 5 1).Table 1. Characteristics of the Study Population and the Unrelated Cord Blood Donors
Pt No. Diagnosis Days of Life at Time of Transplant
HLA Match
(No./Total No.) HLA Mismatch Blood Type Pt Blood Type Donor Pt Sex Unit Sex
Cytopenias without other GVHD manifestations
2 Thalassemia 91 4/6 A31/30;Bbl/7 A+ A+ M M
6 Krabbe 29 4/6 B57/8;DR0402/1302 B+ B+ M M
12 Krabbe 117 5/6 A11/29 O+ A+ M F
13 Krabbe 26 4/6 Abl/11;B39/18 O+ O+ F F
15 Krabbe 22 5/6 DR9/8 O+ O+ F F
19 Krabbe 33 5/6 A31/2 A+ A+ M F
Cytopenias with cGVHD
9 MPS II 44 5/6 DR11/7 O+ A2 M F
10 MPS I 113 4/6 A33/68;DR16/13 B+ A+ M M
16 MLD 62 5/6 A1/3 O+ O+ M F
17 Krabbe 29 4/6 B55/51;DR15/4 A+ O+ F M
No cytopenias or cGVHD
1 MPS I 88 5/6 A28/29 A+ O+ F F
3 Krabbe 55 4/6 A30/25;B44/53 O2 A+ M M
4 Krabbe 29 4/6 A2/33;B39/bl AB+ B+ F M
5 Tay-Sachs 22 4/6 B50/41;DRB1 1302/1303 B+ A+ M M
7 Krabbe 37 5/6 B40/58 O+ A2 F M
8 MPS I 62 5/6 A68/2 O+ O+ F F
11 Krabbe 26 5/6 B18/44 A2 A+ M M
14 Krabbe 22 5/6 B44/14 A2 A+ M M
18 Krabbe 18 4/6 A25/11;B18/44 B+ A+ F M
Mean ± SD 48 ± 31
Median 36
GVHD indicates graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Pt, patient; bl, blank.
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Pt No.
Total Nucleated
Cells Cryopreserved
(107/kg)
Total Nucleated
Cells Reinfused
(107/kg)
Colony-Forming
Units Infused
(104/kg)
CD34+ Cells
Infused
(105/kg)
Cytopenias without other GVHD manifestations
2 31.82 19.10 7.64 6.11
6 39.20 25.00 23.75 5.65
12 14.74 19.90 15.92 3.18
13 13.48 9.92 4.46 1.69
15 18.78 13.20 10.56 8.45
19 42.75 31.60 0 2.84
Cytopenias with cGVHD
9 14.85 10.00 4.50 1.48
10 24.63 20.73 14.51 4.68
16 16.42 12.60 3.15 1.51
17 38.23 27.40 20.55 5.48
No cytopenias or cGVHD
1 18.63 15.70 51.81 8.01
3 21.93 14.20 6.39 1.80
4 19.79 11.50 10.93 1.27
5 18.49 12.41 13.03 1.81
7 17.36 15.84 11.09 3.72
8 12.34 8.42 8.00 1.94
11 17.76 15.40 23.10 2.60
14 50.37 32.40 105.30 11.02
18 33.03 18.60 13.02 7.25
Mean ± SD 24.45 ± 11.27 17.57 ± 7.14 18.30 ± 23.92 4.24 ± 2.86
Median 18.78 15.70 11.08 3.18
GVHD indicates graft-versus-host disease; cGVHD, chronic graft-versus-host disease; Pt, patient.Graft Characteristics
All infants were transplanted with a single unre-
lated cord blood unit selected by cell dose and HLA
matching. The units contained a median TNC before
cryopreservation of 18.78  107/kg of recipient body
weight (range: 12.34  107/kg to 50.37  107/kg
(Table 2). The median number of total nucleated
infused cells were 15.70  107/kg (range: 8.42  107/
kg to 32.40  107/kg). The median numbers of
CD341 cells and CD31 infused were 3.18  105/kg
(range: 1.27  105/kg to 11.02  105/kg) and 26.50 
106/kg (range: 15.23 106/kg to 90.31  106/kg),
respectively. Units were matched at 4 of 6 (n 5 9), or
5 of 6 (n5 10) HLA loci using intermediate resolution
DNA typing for Class I A 1 B and high-resolution
DNA typing for DRB1.
Engraftment and Chimerism
Neutrophil (ANC .500/mm3) and platelet en-
graftment (platelets .50,000 cells/mL) occurred in
a median of 19 days (range: 10 to 40) and 60 days
(range: 30 to 164), respectively (Table 3). The cumula-
tive incidence of neutrophil engraftment at 42 days was
100% (95% confidence interval [CI] 89%-100%) and
platelet engraftment at 180 days was 100% (95% CI
89%-100%). Red cell and platelet transfusions were
no longer required at a median 59 days (range: 17 to
385) and 50 days (range: 25 to 164), respectively. Sev-
enteen of the 18 evaluable infants obtained full donor
chimerism (defined as.98% donor). One infant diag-
nosed with MPS II remained a mixed chimerathroughout his life. An additional infant with meta-
chromatic leukodystrophy experienced secondary
graft failure 2.5 years posttransplant.
aGVHD and cGVHD
In the 18 infants evaluable for aGVHD, 12 had ei-
ther grade 0 (n 5 1) or grade I (n 5 11) (Table 3).
Grades II-IV aGVHD occurred in 6 infants (grade II
n 5 5; grade III n 5 1; grade IV n 5 0). The median
time to onset of among patients with grades II-IV
was 12 days (range: 7-35) with a cumulative incidence
of grades II-IV at 100 days of 33% (95% CI 11%-
56%) (Figure 1). One patient experienced grade III
aGVHD on day 35 posttransplant (Figure 1). Treat-
ment included topical steroids (n 5 10) and methyl-
prednisolone pulse (n 5 7), tacrolimus (n 5 4), and
daclizimab (n 5 4).
The cumulative incidence of cGVHD defined
according to conventional diagnostic criteria [1] was
17% (95% CI 0%-35%) and 23% (95% CI
2%-43%), at 1 and 2 years, respectively (Figure 2A).
One patient had extensive cGVHD involving skin,
gastrointestinal track, and the lung cGVHD, whereas
3 other infants had disease limited disease of the skin
(Table 3). We examined possible factors contributing
to GVHD, including TNC cell dose, HLA-matching,
CD341 cell dose, CD31 cell dose, colony-forming
units, ABO/Rh mismatch, and unit sex. None of these
factors influenced the incidence or severity of aGVHD
or cGVHD in this small patient cohort (data not
shown).
HD
Chronic GVHD Grade Event-Free Survival (Days)§ Cause of Death
Cytopenia 3440
Cytopenia 2684
Cytopenia 1480
Cytopenia 1368
Cytopenia 1321
Cytopenia 353
Cytopenia, Extensive Died Multisystem organ failure
(day 653)
Cytopenia, Limited (Skin) 1879
Cytopenia, Limited (Skin) 1293
Cytopenia, Limited (Skin) 955
None 3468
None 3391
None 2977
None Died Probable infection
(day 1686)
None 2264
None 1986
None 1725
None 1327
NE Died Pulmonary Hypertension
(day 15)
1994 ± 238
1802 (353-3468)
S II, mucopolysaccharidosis type II (Hunter’s Syndrome); MLD, metachromatic leukodys-
ys, and platelet engraftment was defined as a count >50,000 per cubic millimeter without
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Pt No. Diagnosis
Engraftment (Days)*
RBC Transfusion
Independence (Days)†
Chimerism (% Donor)
Acute GV
Grade‡Neutrophil Platelet At 100 Days At 1 Year
Cytopenias without other GVHD manifestations
2 Thalassemia 14 33 17 >99 >99 1
6 Krabbe 20 101 115 >99 >99 1
12 Krabbe 31 91 77 >98 >99 3
13 Krabbe 14 48 55 >98 >98 1
15 Krabbe 25 64 62 94 98 1
19 Krabbe 31 141 385 97 NE 2
Cytopenias with cGVHD
9 MPS II 20 56 52 50 22 1
10 MPS II 14 89 80 >99 >98 2
16 MLD 40 164 190 63 100 1
17 Krabbe 17 49 70 97 100 1
No cytopenias or cGVHD
1 MPS I 10 33 25 >99 >99 0
3 Krabbe 14 53 49 >99 >99 1
4 Krabbe 13 49 39 100 100 1
5 Tay-Sachs 20 90 103 >99 >99 2
7 Krabbe 20 67 53 99 100 1
8 MPS I 19 47 47 >99 >99 2
11 Krabbe 19 74 70 >99 >98 2
14 Krabbe 11 30 51 >98 >98 1
18 Krabbe NE NE NE NE NE NE
Mean ± SE 20 ± 2 71 ± 9 86 ± 20
Median (range) 19 (10-40) 60 (30-164) 59 (17-385)
MPS I indicates mucopolysaccharidosis type I (Hurler’s Syndrome); Krabbe, globoid cell leukodystrophy, Krabbe disease; MP
trophy; EFS, event-free survival; Pt, patient.
*Neutrophil engraftment was defined as an absolute neutrophil count of >500 per cubic millimeter on at least 3 consecutive da
any transfusion support for at least 7 days.
†RBC transfusion independence was defined as 7 days from last transfusion with no further transfusion support needed.
‡The 15 infants with acute graft-versus-host disease (aGVHD) had skin manifestations.
§EFS as of April 1, 2008.
Autoimmune Diseases
Ten infants were diagnosed with an autoimmune
cytopenia (Table 4). The overall cumulative incidence
of autoimmune cytopenias, with or without other
manifestations of cGVHD, was 44% (95% CI 21%-
68%) and 56% (95% CI 32%-80%) at 1 and 2 years,
respectively (Figure 2B and C). The median onset
was 247 days posttransplant (range: 92 to 687). The
cytopenias observed included anemia (n 5 4), throm-
bocytopenia (n 5 1), anemia with thrombocytopenia
(n 5 3), and pancytopenia (n 5 2).
Of the 9 patients with anemia, 8 had a positive
Coombs with IgG polyspecific autoantibodies. Four
patients also had complement fixation noted on red
cells by direct antiglobulin testing. On eluate testing,
the specificity of the antibody was identified as anti-
E in 2 patients with 1 patient having anti-A. Four of
the 6 infants with thrombocytopenia had elevated
levels of direct antiplatelet antibodies.
Nine of the 10 infants developed an autoimmune
cytopenia while on CSA (n 5 6) or tacrolimus (n 5 3)
with methylprednisolone for GVHD treatment or
prophylaxis. One infant was on physiologic doses of
hydrocortisone secondary to adrenal suppression.
Treatment of Autoimmune Cytopenias
All 10 infants received methylprednisolone for
treatment of the cytopenias. Eight infants also received
Rituximab therapy (2 infants were treated prior to
widespread rituximab use). CSA was withdrawn in 5
infants. Other treatments included intravenous immu-
noglobulins (n 5 4), Azathioprine (n 5 7), splenec-
tomy (n 5 1) (Table 4). Erythropoietin was
administered to 1 infant without response. G-CSF
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Figure 1. Cumulative incidence of aGVHD after unrelated cord blood
transplantation in very young infants. Cumulative incidence of grades
II-IV and grades III-IV aGVHD in the study patients is displayed.
Biol Blood Marrow Transplant 14:1108-1117, 2008was used in the 2 infants with neutropenia. Themedian
treatment length was 21 months (range: 8-35).
As of April 2008, 3 of 10 infants are continuing to
receive immunosuppressive therapies for autoimmune
cytopenias. The DAT remains positive in 1 with active
AIHA and 1 other infant who continues with intermit-
tent hemolysis. One infant remains on immunosup-
pression for skin cGVHD.
Comparison with Older Children
We compared the incidence of cGVHD and auto-
immune cytopenias with or without other manifesta-
tions of cGVHD in this group of very young infants
to a cohort of 141 older children (median age 5 1.50
years) with inherited metabolic disease who underwent
cord blood transplantation between August 1995 and
April 2007 at our center [16]. Although the overall in-
cidence of cGVHD in the infants was equivalent to
that of older children (Figure 2A), the cumulative inci-
dence of autoimmune cytopenia with or without other
manifestations of cGVHD for the infants was signifi-
cantly higher at 1 and 2 years (44% [95% CI 21%-
68%] and 56% [95% CI 32%-80%]) compared to
the older children (1 year: 5% [95% CI 1%-8%], 2
years: 6% [95% CI 2%-10%], P\ .01) (Figure 2B).
The cumulative incidence of isolated autoimmune
cytopenias was also significantly higher in the infants
compared to the older children (28% [95% CI 6%-
49%] versus 5% [95% CI 2%-9%], P \ .01)
(Figure 2C).
Survival
As of April 2008, 16 of 19 infants were alive (me-
dian: 1802 days; range: 353 to 3468 days) for an OS
in this cohort of 95% (95% CI 85%-100%),89%
(95% CI 75%-100%), and 80% (95% CI 59%-
100%) at 1, 2, and 5 years, respectively (Table 3).
One infant with Krabbe died on posttransplant day
15 from pulmonary hypertension. An infant with
Hunter’s (MPS II) died 653 days posttransplant from
multisystem organ failure. An infant with Tay-Sachs
died abruptly on day 1686 from unknown causes.
DISCUSSION
In this report, we describe a cohort of younger in-
fants undergoing unrelated, single-unit UCBT for
nonmalignant disorders after myeloablative chemo-
therapy-based conditioning who developed an unex-
pectedly high incidence of posttransplant immune
mediated hematologic disorders. Rates of aGVHD
and cGVHDwere similar to those in previous reports.
No patient had Epstein-Barr Virus lymphoprolifera-
tive disease and none of the immune diseases were trig-
gered by a known viral illness.
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Figure 2. Cumulative incidence of cGVHD (A) and autoimmune cyto-
penias (B, C) in very young infants compared to older children undergo-
ing UCBT. (A) The cumulative incidence of cGVHD in the infant
population (solid line) compared to a historic control group of all otherBecause of their small size, all infants received very
high cell doses from their donor grafts. Engraftment
and survival occurred at higher rates than those expe-
rienced by older children and adults. In this group,
overall survival was 95%, 89%, and 80% at 1, 2, and
5 years, respectively. Neutrophil and platelet engraft-
ment occurred (with a cumulative incidence of
100%) in a median of 19 and 60 days, respectively. In-
fants were treated with therapy first to remove T cell
suppression and then to target B cells. We found that
combination treatment with steroids, rituximab, and/
or azithioprine was most effective. In contrast to other
reports [3-5,7], there was increase in mortality associ-
ated with the development of an autoimmune cytope-
nia. Rather, this cohort exhibited an excellent response
to therapy and an excellent OS.
AIHA and other immune cytopenias have been re-
ported in both adults and children undergoing alloge-
neic HSCT. In adults, Drobyski et al. [3] reported an
overall incidence of AIHA of 3% in patients receiving
T cell-depleted grafts with an incidence of 5% in
patients who survived .6 months (3). Chen et al. [4]
reviewed data from 293 patients and noted that the pa-
tients fell into 2 distinct groups: an early onset (2-8
months) with a cold antibody and a late onset (6-18
months) associated with a warm antibody. Sanz et al.
[5] described 272 patients with an overall incidence
of AIHA of 4.44%. Independent risk factors identified
for AIHA included HSCT from an unrelated donor
and the presence of extensive cGVHD. In contrast to
the young patients in this report, AIHA in adults was
associated with a poor overall prognosis, although of-
ten not directly because of the process [3-5,7]. O’Brien
et al. [7] described the largest series of pediatric pa-
tients who received unrelated donor HSCT with 19
(6%) of 303 patients developing AIHA. None of the
patients who received a related donor transplant in
their series developed AIHA (n5 136). In their series,
children\10 years of age and those undergoing trans-
plant for nonmalignant diagnosis (specifically meta-
bolic diseases) were significantly more likely to
develop AIHA as a posttransplant complication. Both
stem cell source and graft manipulation to deplete T
cells were not found to be risk factors, which are in
contrast to other reports [3,6]. There was no difference
in the overall rate of cGVHD in children who devel-
oped AIHA and those who did not. A high rate of
mortality (53%) was reported in children developing
AIHA in this series.
metabolic patients treated at Duke (dotted line). (B) The cumulative in-
cidence of autoimmune cytopenias in the study patients (solid line) com-
pared to the older control group of all other metabolic patients treated
at Duke (dotted line). (C) The cumulative incidence of cytopenias with-
out other manifestations of cGVHD between the infants (solid line) and
older children (dotted line).
ytopenia
Plt
tibody
Tacrolimus
Exposure Treatment Outcome
No Methylpred, IVIG,
Azathioprine
Alive. Resolved.
No Methylpred, IVIG,
d/c CSA
Alive. Resolved.
No Methylpred, IVIG,
Azathioprine,
Rituximab
Alive. On treatment
with intermittent
hemolysis.
Yes Methylpred,
Azathioprine,
Rituximab, d/c CSA
Alive. Resolved.
Yes Methylpred,
Azathioprine,
Rituximab,
EPO, GCSF, d/c CSA
Alive. Continues on
azathioprine
(weaning).
No Methylpred,
Azathioprine,
Rituximab
Alive. On treatment.
Yes Methylpred, IVIG,
Azathioprine,
Rituximab,
Splenectomy, d/c CSA
Died of multisystem
organ failure. Had
secondary
graft failure and
underwent
second transplant.
Yes Methylpred, Rituximab
(daclizimab for
skin GVHD)
Alive. Resolved.
No Methylpred, Rituximab Alive. Ongoing
pancytopenia.
Secondary
graft failure
requiring
second transplant.
Yes Methylpred,
Azathioprine,
Rituximab, d/c CSA
Alive. On
azathioprine
and steroids for skin
cGVHD.
metachromatic leukodystrophy; DAT, direct antibody testing; Methylpred, methyl-
D, graft-versus-host disease; Pt, patient.
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Pt
No.
Pretranplant
Diagnosis
Initial GVHD
Prophylaxis
Type of
Cytopenia
Posttransplant
Onset (Days)
RBC
Antibody An
Cytopenias without other GVHD manifestations
2 Beta-thalassemia CsA, Methypred AIHA,
thrombocytopenia
131 IgG+ panreactive
6 Krabbe CsA, Methypred Thrombocytopenia 279
12 Krabbe CsA, Methypred AIHA 503 IgG+, panreactive,
C3+
13 Krabbe CsA, Methypred AIHA 183 IgG+ panreactive,
C3+
15 Krabbe CsA, Methypred AIHA,
thrombocytopenia,
neutropenia
132 IgG+, panreactive,
C3+
Yes
19 Krabbe CsA, MMF AIHA 320 IgG+, panreactive
(Anti-e, C)
Cytopenias with cGVHD
9 MPS II CsA, Methypred AIHA,
thrombocytopenia
92 IgG+ panreactive,
C3+, (Anti-E)
Yes
10 MPS II CsA, Methypred AIHA,
thrombocytopenia
283 IgG+, C3+,
(Anti-A)
Yes
16 MLD CsA, MMF AIHA,
thrombocytopenia,
neutropenia
687 Yes
17 Krabbe CsA, MMF AIHA 215 IgG+ panreactive,
(Anti-E)
Krabbe indicates globoid cell leukodystrophy (Krabbe disease); MPS II, mucopolysaccaridosis type II (Hunter’s Syndrome); MLD,
prednisolone; CSA, cyclosporine; MMF, mycophenolate; EPO, erythropoietin; G-CSF, granulocyte-colony stimulating factor; GVH
1116 Biol Blood Marrow Transplant 14:1108-1117, 2008K. M. Page et al.Horn et al. [6] described a high incidence (19.5%)
of AIHA in a series of 41 children with SCID after T
cell-depleted haploidentical bone marrow or PBSC
transplantation. The incidence was 6% in patients
who survived .6 months, which is comparable to
other reports. All infants were found to have de-
creased CD4 and/or CD8 cells posttransplant. They
hypothesized that the paucity of regulatory T cells al-
lowed for B cell clonal expansion resulting in the au-
toimmune phenomena. Godder et al. [17] described
40 patients with hematologic malignancies or marrow
failure who survived .120 days. Five of the 40 pa-
tients developed AIHA as the principal manifestation
of cGVHD after receiving T cell-depleted partially
mismatched related donor BMT. Immune function
recovery was not different in the affected patients.
aGVHD was also not noted to be a risk factor. It
was proposed that HLA mismatch may have been
a risk factor in addition to the T cell depletion pro-
cess. Isolated case reports also exist, which describe
AIHA and other cytopenias in children after all types
of HSCT [18-26].
There are also rare case reports of patients devel-
oping autoimmune cytopenias from 6-9 years after car-
diac transplantation (age: 7 months 4 years). Tubman
et al. [27] described 3 pediatric patients with autoim-
mune cytopenias and hypothesized that the significant
B cell immunosuppression by calcineurin inhibitions
was a risk factor for development of the cytopenia.
All were treated with and responded to rituximab ther-
apy. Rawal et al. [28] described a pediatric patient
transplanted at 15 months of age who developed at
age 11 years multiple episodes of autoimmune cytope-
nias (anemia, thrombocytopenia, and neutropenia)
and acquired glanzmann thrombasthenia several years
after cardiac transplantation. This patient initially
presented with a presumed viral myocarditis that may
have recapitulated robust antibody formation.
The pathogenesis of autoimmune cytopenias in
these young patients is not clear at this time. It may
be because of an effect of treatment with calcineurin
inhibitors or ATG on the developing thymus. All pa-
tients in this series received GVHD prophylaxis with
cyclosporine, which is known to inhibit thymic-depen-
dent clonal deletion, which disrupts the reconstitution
of the immune system [29]. CSA also suppresses IL-2-
dependent proliferation and function of regulatory T
cells, which could then lead to the development of au-
toimmune disease [30]. However, this does not fully
explain the increased incidence of autoimmune disease
in these very young patients compared to our older pa-
tient cohort, who were also receiving cyclosporine for
prophylaxis against GVHD. It is possible that the rel-
atively higher T cell dose given to these patients from
the cord blood unit graft may have accentuated the risk
of both GVHD and immune dysregulation in the
setting of CSA therapy. Future studies, characterizingthe composition of the T cell compartment at the time
of onset of autoimmune disease, may elucidate the
mechanism underlying this problem.
In this report, we present the outcomes of a cohort
of very young infants undergoing UCBT for genetic
disorders in the first few months of life. We observed
a markedly increased rate of posttransplant autoim-
mune cytopenias. In these patients, we suspect this
was because of immune dysregulation associated with
GVHDprophylaxis during the first year of life, leading
to aberrant immune ontogeny. We are planning a pro-
spective study to characterize the early phases of im-
mune reconstitution in this unique group of patients.
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